US Patent

US9157082 — Modulation of apolipoprotein CIII (ApoCIII) expression

Method of Use · Assigned to Isis Pharmaceuticals Inc · Expires 2032-04-27 · 6y remaining

Vulnerability score 81/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods and compositions for reducing ApoCIII expression and increasing HDL levels to treat or prevent cardiovascular disease or metabolic disorder.

USPTO Abstract

Provided herein are methods, compounds, and compositions for reducing expression of ApoCIII mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for increasing HDL levels and/or improving the ratio of TG to HDL and reducing plasma lipids and plasma glucose in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate any one or more of cardiovascular disease or metabolic disorder, or a symptom thereof.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-4050 — olezarsen-sodium

Patent Metadata

Patent number
US9157082
Jurisdiction
US
Classification
Method of Use
Expires
2032-04-27
Drug substance claim
No
Drug product claim
No
Assignee
Isis Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.